News
Wegovy, Novo Nordisk and MASH
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
Pharmaceutical Technology on MSN14h
Wegovy becomes first GLP-1RA to gain FDA MASH approval
The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback